Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
2023年6月29日 - 7:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
|
Filed by a party other than the Registrant ☐
|
Check the appropriate box:
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive Proxy Statement
|
☒
|
Definitive Additional Materials
|
☐
|
Soliciting Material Pursuant to Sec.240.14a-12
|
Infinity Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒
|
No fee required.
|
☐
|
Fee paid previously with preliminary materials.
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
Infinity Pharmaceuticals (NASDAQ:INFI)
過去 株価チャート
から 10 2024 まで 11 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
過去 株価チャート
から 11 2023 まで 11 2024
Real-Time news about Infinity Pharmaceuticals Inc (ナスダック市場): 0 recent articles
その他のInfinity Pharmaceuticals Incニュース記事